Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : UC Davis - Children 12 to 15 can now be vaccinated against COVID-19

05/14/2021 | 07:26am EDT

Pediatric infectious disease expert encourages parents and caregivers to immunize adolescents

UC Davis Health experts are advising parents to get their 12- to 15-year-olds vaccinated against COVID-19. The U.S. Food and Drug Administration (FDA) has approved the Emergency Use Authorization to allow adolescents to get the vaccine made by Pfizer. The U.S. Centers for Disease Control and Prevention (CDC) has also adopted an advisory committee's recommendation on the safety of the vaccine for this age group.

'The FDA's expansion of the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine to include adolescents 12 through 15 years of age is a significant step in the fight against the COVID-19 pandemic,' said acting FDA commissioner Janet Woodcock. 'Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations.'

The Pfizer vaccine consists of two shots, spaced 21 days apart. The Pfizer vaccine is, so far, the only one approved for youths 12 and up. UC Davis Health is ready to vaccinate children in this age group with parent or guardian permission.

Why vaccinate kids against COVID-19?

The pandemic has been driven largely by adults, who have had more severe disease than children, but that's changing.

'Many people don't realize that children now account for more than 20% of cases in the U.S.,' said Dean Blumberg, chief of pediatric infectious diseases at UC Davis Health. 'Those who are most vulnerable to infection are those who aren't vaccinated.'

Vaccination is also important for children's overall health. 'This will allow children to take advantage of all the opportunities for social interaction that are now recommended for fully vaccinated adults by the CDC, including going to other households,' explained Blumberg.

He also pointed out that vaccinating kids will help protect their loved ones. 'Children can bring infection back into families, even transmitting to immunized individuals, because no vaccine works 100%.' He said vaccination allows for peace of mind as children return to school, sports and other activities.

Are children as well protected by the vaccine as adults?

According to Pfizer, the vaccine was 100% effective in the trial for children aged 12-15. More than 2,200 youths were enrolled in the study. Eighteen cases of COVID-19 came up in the placebo group.

'The trial shows the immunization is clearly protective,' Blumberg said.

COVID-19 vaccine trials with children as young as 6 months of age are taking place now.


Public Affairs

Phone: 916-734-9040

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about PFIZER, INC.
02:48aPhilippines seals deal for 40 mln Pfizer/BioNTech COVID-19 doses
02:14aPhilippines' vaccine procurement chief confirms supply agreement with pfizer-..
01:41aPhilippines signs deal for 40 mln Pfizer/BioNTech vaccine doses - report
01:41aPhilippine government has signed a supply deal for 40 million doses of pfizer..
06/19PFIZERá : Quebec pauses Pfizer shots at walk-in clinics for several days over de..
06/19PFIZERá : Aussie MP Hails Zimbabwe's Covid-19 Vaccination Campaign
06/18Ontarians cancelling AZ doses after new guidance, province still offering dos..
06/18PFIZERá : Palestinians call off 1M dose vaccine exchange with Israel
06/18MODERNAá : Vaccine deliveries enough to fully vaccinate all eligible Canadians b..
06/18BIONTECHá : Israel to Deliver Soon-to-Expire COVID-19 Jabs to Palestine
More news
Financials (USD)
Sales 2021 72 838 M - -
Net income 2021 17 466 M - -
Net Debt 2021 26 268 M - -
P/E ratio 2021 13,2x
Yield 2021 4,06%
Capitalization 217 B 217 B -
EV / Sales 2021 3,34x
EV / Sales 2022 3,94x
Nbr of Employees 78 500
Free-Float 59,2%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 24
Average target price 42,34 $
Last Close Price 38,81 $
Spread / Highest target 36,6%
Spread / Average Target 9,10%
Spread / Lowest Target -7,24%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER, INC.5.43%217 246
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795